Background
The life expectancy and treatment options for the patients with hepatocellular carcinoma HCC presented with portal vein thrombosis are frustrating. This study...
Pimavanserin, a selective serotonin inverse agonist/antagonist at the 5-HT2A/C receptors, is being actively studied for multiple indications. The CLARITY clinical trial program is evaluat...
Up to 70% of individuals with schizophrenia experience inadequate response to antipsychotic treatment potentially due to insufficient exposure due to nonadherence or to medication ineffec...